Piper Jaffray analyst Tyler Van Buren raised his price target on BeiGene to $180 and kept his Overweight rating after its Q1 results showing sales of Abraxane, Revlimid, and Vidaza in China experiencing a “very nice” sequential rebound after flat performance in Q4. The analyst is also positive on the company’s growth driven by increased reimbursement coverage and the Revlimid label expansion in newly-diagnosed patients, as well as its prospects from the three applications that are currently undergoing priority review in China, with “potential approvals and launches coming soon.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.